Related Experiment Video
Updated: Aug 14, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy
Insights
Duchenne and Becker muscular dystrophies cause progressive muscle weakness and cardiac issues. This policy provides guidelines for timely cardiovascular evaluation in affected individuals.
Area of Science:
- Neurology
- Cardiology
- Genetics
Background:
- Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are severe genetic disorders.
- These conditions lead to progressive skeletal muscle weakness, respiratory compromise, and cardiac failure.
- The natural history of cardiomyopathy in DMD and BMD is not well understood, leading to delayed cardiac evaluations.
Purpose of the Study:
- To establish recommendations for optimal cardiovascular evaluation in individuals with confirmed DMD or BMD.
- To guide healthcare specialists in managing the cardiac aspects of these muscular dystrophies.
Main Methods:
- This is a policy statement, not a research study.
- It synthesizes current knowledge and expert opinion.
- Recommendations are based on established clinical practice and literature review.
Main Results:
- Cardiovascular complications are a major cause of morbidity and mortality in DMD and BMD.
- Current practice often delays cardiac assessment until symptoms are apparent.
- Proactive and regular cardiovascular evaluation is crucial.
Conclusions:
- Early and consistent cardiovascular monitoring is essential for patients with DMD and BMD.
- Implementing these recommendations can improve patient outcomes.
- This policy aims to standardize and optimize cardiac care for individuals with these conditions.
Abstract:
Duchenne muscular dystrophy is the most common and severe form of the childhood muscular dystrophies. The disease is typically diagnosed between 3 and 7 years of age and follows a predictable clinical course marked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or cardiac failure. Becker muscular dystrophy is less common and has a milder clinical course but also results in respiratory and cardiac failure. The natural history of the cardiomyopathy in these diseases has not been well established. As a result, patients traditionally present for cardiac evaluation only after clinical symptoms become evident. The purpose of this policy statement is to provide recommendations for optimal cardiovascular evaluation to health care specialists caring for individuals in whom the diagnosis of Duchenne or Becker muscular dystrophy has been confirmed.
More Related Videos
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
06:52Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management
Satellite Stem Cells and Muscular Dystrophy
Assessment of the Cardiovascular System II: Inspection
Head and Neck